# US 2020/0399318 A1 · Peptide inhibitors of phosphoglycerate mutase and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399318 A1
- Document ID: US20200399318A1
- Status: Published application
- Kind: A1
- Application number: 17/016,168
- Filed: 2020-09-09
- Published: 2020-12-24
- Earliest claimed: 2016-08-11
- Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services; The University of Tokyo; New England Biolabs, Inc.
- Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services; The University of Tokyo; New England Biolabs, Inc.
- Inventors: James Inglese; Patricia Dranchak; Ryan MacArthur; Hiroaki Suga; Hao Yu; Clotilde Carlow; Zhiru Li
- Web page: https://patentgrep.com/patent/US20200399318A1

## CPC

- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 33/10: Anthelmintics
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.

## Claims

### Claim 1

An isolated peptide comprising the amino acid sequence of any one of SEQ ID NOs: 7-9.

### Claim 2 (depends on 1)

The isolated peptide of claim 1, wherein the N-terminal amino acid is D-N-chloroacetyl tyrosine.

### Claim 3 (depends on 2)

The isolated peptide of claim 2, wherein the peptide comprises:
(SEQ ID NO: 7)
Ac-DYDYPGDYSYLYGTCG;
(SEQ ID NO: 8)
Ac-DYDYPGDYSYLY;
or
(SEQ ID NO: 9)
Ac-DYLYGTCG.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising the isolated peptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 1)

A method of treating or inhibiting infection with an organism expressing at least one cofactor-independent phosphoglycerate mutase in a subject, comprising administering to the subject an effective amount of the isolated peptide of claim 1.

### Claim 6 (depends on 5)

The method of claim 5, wherein the subject is infected with an organism selected from the group consisting of a nematode, a trypanosome, a helminth, a protozoan parasite, or a bacterium.

### Claim 7 (depends on 6)

The method of claim 6, wherein the subject is infected with a nematode, and the nematode comprises one or more of Brugia malayi, Brugia timori, Wuchereria bancrofti, Onchocerca volvulus, Loa, Mansonella streptocerca, Mansonella perstans, Mansonella ozzardi, Dirofilaria immitis, Trichinella, Parafilaria bovicola, Onchocerca dermatan, Onchocerca ochengi, Onchocerca dukei, Stenofilaria assamensis, and Parafilaria multipapillosa.

### Claim 8 (depends on 6)

The method of claim 6, wherein the subject is infected with a bacterium and the bacterium comprises one or more of Staphylococcus aureus, Bacillus anthracia, Streptococcus pneumoniae, and Escherichia coli.

### Claim 9 (depends on 5)

The method of claim 5, wherein the peptide is administered to the subject orally, intravenously, or topically.

### Claim 10 (depends on 5)

The method of claim 5, further comprising administering one or more of an antiparasitic or antibiotic agent to the subject.

### Claim 11

An isolated cyclic peptide comprising the any one of the peptides in FIG. 21, SEQ ID NO: 21 or SEQ ID NO: 22.

### Claim 12 (depends on 11)

The isolated cyclic peptide of claim 11, wherein the peptide comprises:

### Claim 13 (depends on 11)

A pharmaceutical composition comprising the isolated cyclic peptide of claim 11 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 11)

A method of treating or inhibiting infection with an organism expressing at least one cofactor-independent phosphoglycerate mutase in a subject, comprising administering to the subject an effective amount of the isolated cyclic peptide of claim 11.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject is infected with an organism selected from the group consisting of a nematode, a trypanosome, a helminth, a protozoan parasite, or a bacterium.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject is infected with a nematode, and the nematode comprises one or more of Brugia malayi, Brugia timori, Wuchereria bancrofti, Onchocerca volvulus, Loa loa, Mansonella streptocerca, Mansonella perstans, Mansonella ozzardi, Dirofilaria immitis, Trichinella, Parafilaria bovicola, Onchocerca dermatan, Onchocerca ochengi, Onchocerca dukei, Stenofilaria assamensis, and Parafilaria multipapillosa.

### Claim 17 (depends on 15)

The method of claim 15, wherein the subject is infected with a bacterium and the bacterium comprises one or more of Staphylococcus aureus, Bacillus anthracia, Streptococcus pneumoniae, and Escherichia coli.

### Claim 18 (depends on 14)

The method of claim 14, wherein the cyclic peptide is administered to the subject orally, intravenously, or topically.

### Claim 19 (depends on 14)

The method of claim 14, further comprising administering one or more of an antiparasitic or antibiotic agent to the subject.
